Julie Bruneau

Julie Bruneau

Auto-generated profile, based on publicly available information

Julie Bruneau

INSERM U1163, Laboratoire de physiopathologie et de traitement des troubles hématologiques, Institut Imagine, Université Paris Cité, Hôpital Universitaire Necker - Enfants Malades, Paris, France

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2016 in Blood
Verified
Journal Article
Open access
PDF file
DVDavid Vallois
David Vallois
MDMaria Pamela D. Dobay
Maria Pamela D. Dobay
RMRyan D. Morin
Ryan D. Morin
FLFrançois Lemonnier
François Lemonnier
EMEdoardo Missiaglia
Edoardo Missiaglia
LLLaurence de Leval
Laurence de Leval
Angioimmunoblastic T-cell lymphoma (AITL) and other lymphomas derived from follicular T-helper cells (TFH) represent a large proportion of peripheral T-cell lymphomas (PTCL) with poorly understood pathogenesis and unfavorable treatment results. We investigated a series of 85 patients with AITL (n=72) or other TFH-derived PTCL (n=13) by targeted deep sequencing of a gene panel enriched in T-cell receptor (TCR) signaling elements. RHOA mutations were identified in 51/85 cases (60%) consisting of the highly recurrent dominant negative G17V variant in most cases and a novel K18N in 3 cases, the latter showing activating properties in in vitro assays. Moreover, half of the patients carried virtually mutually exclusive mutations in other TCR-related genes, most frequently in PLCG1 (14.1%), CD28 (9.4%, exclusively in AITL), PI3K elements (7%), CTNNB1(6%) and GTF2I (6%). By in vitro assays in transfected cells, we demonstrated that 9/10 PLCG1 and 3/3 CARD11 variants induced MALT1 protease activity and increased transcription from NFAT or NF-kB response element reporters, respectively. Collectively, the vast majority of variants in TCR-related genes could be classified as gain-of-function. Accordingly, the samples with mutations in TCR-related genes other than RHOA had transcriptomic profiles enriched in signatures reflecting higher T-cell activation. Although no correlation with presenting clinical features nor significant impact on survival was observed , the presence of TCR-related mutations correlated with early disease progression. Thus, targeting of TCR-related events may hold promise for the treatment of TFH-derived lymphomas.

12 September 2016 in Nature Immunology
Verified
Journal Article
Open access
PDF file
FVFrédéric Vély
Frédéric Vély
VBVincent Barlogis
Vincent Barlogis
BVBlandine Vallentin
Blandine Vallentin
BNBénédicte Neven
Bénédicte Neven
CPChristelle Piperoglou
Christelle Piperoglou
ÉVÉric Vivier
Éric Vivier
The importance of human innate lymphoid cells to normal human physiology is unclear. Vivier and colleagues find that immunodeficient patients ‘rescued’ with normal bone marrow can recover their T cells but not their innate lymphoid cells, yet remain entirely asymptomatic for nearly 40 years. Innate lymphoid cells (ILCs) have potent immunological functions in experimental conditions in mice, but their contributions to immunity in natural conditions in humans have remained unclear. We investigated the presence of ILCs in a cohort of patients with severe combined immunodeficiency (SCID). All ILC subsets were absent in patients with SCID who had mutation of the gene encoding the common γ-chain cytokine receptor subunit IL-2Rγ or the gene encoding the tyrosine kinase JAK3. T cell reconstitution was observed in patients with SCID after hematopoietic stem cell transplantation (HSCT), but the patients still had considerably fewer ILCs in the absence of myeloablation than did healthy control subjects, with the exception of rare cases of reconstitution of the ILC1 subset of ILCs. Notably, the ILC deficiencies observed were not associated with any particular susceptibility to disease, with follow-up extending from 7 years to 39 years after HSCT. We thus report here selective ILC deficiency in humans and show that ILCs might be dispensable in natural conditions, if T cells are present and B cell function is preserved.

1 July 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
EEElodie Elkaim
Elodie Elkaim
BNBenedicte Neven
Benedicte Neven
JBJulie Bruneau
Julie Bruneau
KMKanako Mitsui-Sekinaka
Kanako Mitsui-Sekinaka
ASAurelie Stanislas
Aurelie Stanislas
SKSven Kracker
Sven Kracker
Activated phosphoinositide 3-kinase δ syndrome (APDS) 2 (p110δ-activating mutations causing senescent T cells, lymphadenopathy, and immunodeficiency [PASLI]-R1), a recently described primary immunodeficiency, results from autosomal dominant mutations in PIK3R1, the gene encoding the regulatory subunit (p85α, p55α, and p50α) of class IA phosphoinositide 3-kinases. We sought to review the clinical, immunologic, and histopathologic phenotypes of APDS2 in a genetically defined international patient cohort. The medical and biological records of 36 patients with genetically diagnosed APDS2 were collected and reviewed. Mutations within splice acceptor and donor sites of exon 11 of the PIK3R1 gene lead to APDS2. Recurrent upper respiratory tract infections (100%), pneumonitis (71%), and chronic lymphoproliferation (89%, including adenopathy [75%], splenomegaly [43%], and upper respiratory tract lymphoid hyperplasia [48%]) were the most common features. Growth retardation was frequently noticed (45%). Other complications were mild neurodevelopmental delay (31%); malignant diseases (28%), most of them being B-cell lymphomas; autoimmunity (17%); bronchiectasis (18%); and chronic diarrhea (24%). Decreased serum IgA and IgG levels (87%), increased IgM levels (58%), B-cell lymphopenia (88%) associated with an increased frequency of transitional B cells (93%), and decreased numbers of naive CD4 and naive CD8 cells but increased numbers of CD8 effector/memory T cells were predominant immunologic features. The majority of patients (89%) received immunoglobulin replacement; 3 patients were treated with rituximab, and 6 were treated with rapamycin initiated after diagnosis of APDS2. Five patients died from APDS2-related complications. APDS2 is a combined immunodeficiency with a variable clinical phenotype. Complications are frequent, such as severe bacterial and viral infections, lymphoproliferation, and lymphoma similar to APDS1/PASLI-CD. Immunoglobulin replacement therapy, rapamycin, and, likely in the near future, selective phosphoinositide 3-kinase δ inhibitors are possible treatment options.

8 February 2015 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
CMC. Méni
C. Méni
JBJ. Bruneau
J. Bruneau
SGS. Georgin-Lavialle
S. Georgin-Lavialle
LPL. Le Saché de Peufeilhoux
L. Le Saché de Peufeilhoux
GDG. Damaj
G. Damaj
CBC. Bodemer
C. Bodemer

23 December 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KIKazushi Izawa
Kazushi Izawa
EMEmmanuel Martin
Emmanuel Martin
CSClaire Soudais
Claire Soudais
JBJulie Bruneau
Julie Bruneau
DBDavid Boutboul
David Boutboul
SLSylvain Latour
Sylvain Latour
Epstein-Barr virus (EBV) infection in humans is a major trigger of malignant and nonmalignant B cell proliferations. CD27 is a co-stimulatory molecule of T cells, and inherited CD27 deficiency is characterized by high susceptibility to EBV infection, though the underlying pathological mechanisms have not yet been identified. In this study, we report a patient suffering from recurrent EBV-induced B cell proliferations including Hodgkin’s lymphoma because of a deficiency in CD70, the ligand of CD27. We show that EBV-specific T lymphocytes did not expand properly when stimulated with CD70-deficient EBV-infected B cells, whereas expression of CD70 in B cells restored expansion, indicating that CD70 on B cells but not on T cells is required for efficient proliferation of T cells. CD70 was found to be up-regulated on B cells when activated and during EBV infection. The proliferation of T cells triggered by CD70-expressing B cells was dependent on CD27 and CD3 on T cells. Importantly, CD27-deficient T cells failed to proliferate when stimulated with CD70-expressing B cells. Thus, the CD70–CD27 pathway appears to be a crucial component of EBV-specific T cell immunity and more generally for the immune surveillance of B cells and may be a target for immunotherapy of B cell malignancies.

28 November 2013 in Blood
Verified
Journal Article
Closed access
PDF file
BNBénédicte Neven
Bénédicte Neven
Emilie MamessierEmilie Mamessier
Emilie Mamessier
JBJulie Bruneau
Julie Bruneau
SKSophie Kaltenbach
Sophie Kaltenbach
DKDaniel Kotlarz
Daniel Kotlarz
AFAlain Fischer
Alain Fischer
Key Points: Human inherited IL-10 receptor deficiency is associated with a very high risk of non-EBV–related diffuse large B-cell lymphoma. IL-10 signaling may be involved in the immune control of germinal center B-cell lymphoma.